"Cholesterol, LDL" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol.
| Descriptor ID |
D008078
|
| MeSH Number(s) |
D04.210.500.247.808.197.244 D10.532.515.500 D10.570.938.208.275 D12.776.521.550.500
|
| Concept/Terms |
Cholesterol, LDL- Cholesterol, LDL
- Low Density Lipoprotein Cholesterol
- beta-Lipoprotein Cholesterol
- Cholesterol, beta-Lipoprotein
- beta Lipoprotein Cholesterol
- LDL Cholesterol
|
Below are MeSH descriptors whose meaning is more general than "Cholesterol, LDL".
Below are MeSH descriptors whose meaning is more specific than "Cholesterol, LDL".
This graph shows the total number of publications written about "Cholesterol, LDL" by people in this website by year, and whether "Cholesterol, LDL" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 3 | 3 |
| 1997 | 2 | 1 | 3 |
| 1998 | 1 | 1 | 2 |
| 1999 | 0 | 3 | 3 |
| 2000 | 3 | 7 | 10 |
| 2001 | 2 | 9 | 11 |
| 2002 | 1 | 5 | 6 |
| 2003 | 5 | 4 | 9 |
| 2004 | 2 | 6 | 8 |
| 2005 | 5 | 2 | 7 |
| 2006 | 4 | 4 | 8 |
| 2007 | 6 | 6 | 12 |
| 2008 | 5 | 15 | 20 |
| 2009 | 7 | 6 | 13 |
| 2010 | 3 | 3 | 6 |
| 2011 | 1 | 7 | 8 |
| 2012 | 2 | 2 | 4 |
| 2013 | 2 | 4 | 6 |
| 2014 | 3 | 6 | 9 |
| 2015 | 0 | 10 | 10 |
| 2016 | 0 | 3 | 3 |
| 2017 | 1 | 4 | 5 |
| 2018 | 5 | 5 | 10 |
| 2019 | 1 | 3 | 4 |
| 2020 | 1 | 4 | 5 |
| 2021 | 2 | 2 | 4 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 9 | 9 |
| 2024 | 2 | 1 | 3 |
| 2025 | 5 | 3 | 8 |
| 2026 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cholesterol, LDL" by people in Profiles.
-
Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials. Eur Heart J. 2026 Jul 07; 47(26):3404-3414.
-
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial. Nat Med. 2026 Mar; 32(3):1052-1060.
-
Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease. J Prev Alzheimers Dis. 2026 Jan; 13(1):100394.
-
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
-
A prometabolite strategy inhibits cardiometabolic disease in an ApoE-/- murine model of atherosclerosis. JCI Insight. 2025 08 08; 10(15).
-
Estimated Theoretical Benefit of Aggressive LDL Lowering in Patients With Symptomatic Intracranial Atherosclerosis. Neurology. 2025 Jul 08; 105(1):e213768.
-
Real-World Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective-Brief Report. Arterioscler Thromb Vasc Biol. 2025 07; 45(7):1310-1315.
-
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025 Jul 03; 393(1):51-61.
-
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025 05 17; 405(10491):1757-1768.
-
Impact of Batoclimab Treatment on LDL-C with and Without Coadministration of Atorvastatin: Results from a Phase I Randomized Study in Healthy Participants. Drug Saf. 2025 Sep; 48(9):993-1004.